Choose Language
Select a language for news translation.
Vertex’s cystic fibrosis drugs improve protein function but don’t fix the genetic cause, leaving a gap Sionna Therapeutics aims to fill with a therapy that cou…
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026 , James Zou, associat…
Researchers at RIKEN have discovered that artificial cells can reveal fundamental physical principles governing how living cells change shape, driven by the ac…
Written by Brendan Coffey for The Motley Fool -> State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio than VanEck Biotec…
Written by James Halley for The Motley Fool -> Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen. Its l…
Written by Sara Appino for The Motley Fool -> State Street Health Care Select Sector SPDR ETF provides a much lower expense ratio of 0.08% compared to the 0.35…
Written by James Halley for The Motley Fool -> Druckenmiller bought 316,000 shares of Revolution Medicines in the first quarter. The company doesn't generate r…
Researchers at the Indian Institute of Technology Gandhinagar (IITGN) and the Regional Centre for Biotechnology, Faridabad, have developed and tested a new cla…
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechn…
Written by Andy Gould for The Motley Fool -> The Health Care Select Sector SPDR Fund (XLV) carries a lower expense ratio and a higher dividend yield than the …
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Bio…
